Page last updated: 2024-12-07

cb 10375

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

trimelamol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID92368
CHEMBL ID133987
SCHEMBL ID1419460
MeSH IDM0141816

Synonyms (34)

Synonym
64124-21-6
trimethyl tmm
NSC283162 ,
[[4,6-bis[hydroxymethyl(methyl)amino]-1,3,5-triazin-2-yl]-methyl-amino]methanol
methanol, {[1,3,5-triazine-2,4,6-triyltris(methylimino)]tris-}
((4,6-bis((hydroxymethyl)(methyl)amino)-1,3,5-triazin-2-yl)(methyl)amino)methanol
NCI60_002322
NCIMECH_000583
cb-10375
trimelamol
cb 10375
nsc 283162
n(2),n(4),n(6)-trihydroxymethyl-n(2),n(4),n(6)-trimethylmelamine
trimethyloltrimethylmelamine
((s-triazine-2,4,6-triyl)trimethyltrinitrilo)trimethanol
brn 4261541
methanol, (1,3,5-triazine-2,4,6-triyltris(methylimino))tris-
cb-10-375
methanol, ((s-triazine-2,4,6-triyl)trimethyltrinitrilo)tri-
nsc-283162
methanol,3,5-triazine-2,4,6-triyltris(methylimino)]tris-
CHEMBL133987
ust4z70290 ,
unii-ust4z70290
CCG-35699
MHVFYGIQJNFWGQ-UHFFFAOYSA-N
[(4,6-bis[(hydroxymethyl)(methyl)amino]-1,3,5-triazin-2-yl)(methyl)amino]methanol #
SCHEMBL1419460
DTXSID70214334
cb 10-375
methanol, 1,1',1''-(1,3,5-triazine-2,4,6-triyltris(methylimino))tris-
methanol, (s-triazine-2,4,6-triyltris(methylimino))tri-
n,n',n''-trimethyl-n,n',n''-trimethylolmelamine
((1,3,5-triazine-2,4,6-triyl)tris(methylazanediyl))trimethanol

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic analysis was performed at all dose levels on both schedules and a linear correlation was demonstrated between dose and area under the curve."( Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
Abel, G; Ashley, SE; Cairnduff, F; Calvert, AH; Evans, BD; Graham, MA; Gumbrell, LA; Judson, IR; Rutty, CJ; Wilman, DE, 1989
)
0.28
" Pharmacokinetic studies in mouse, rat and man did not show the major species differences characteristic of PMM."( Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.
Abel, G; Goddard, PM; Harrap, KR; Judson, IR; Newell, DR; Rutty, CJ, 1986
)
0.27

Dosage Studied

ExcerptRelevanceReference
" The present studies were conducted to provide a stable parenteral dosage form of trimelamol, which could be used for clinical evaluation of the drug and also be manufactured on a commercial scale without undue drug decomposition occurring."( Development of a parenteral formulation of trimelamol, a synthetic S-triazine carbinolamine-containing cytotoxic agent.
Denham, AJ; Gibson, M; Payne, NI; Taylor, PM,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID23178Half-life was determined in 5%dextrose at 4.0 pH at room temperature1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.
AID73022In vitro cytotoxicity against GCT / cisR cell lines1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID23181Half-life was determined in water at 5.0 pH at room temperature1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID23177Half-life was determined in 0.9%sodium chloride at 5.2 pH at room temperature1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.
AID23182Half-life was determined in water at 7.5 pH at 37 degree C1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.
AID156675In vitro cytotoxicity against PC6 murine plasmacytoma cell lines1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.
AID23180Half-life was determined in water at 5.0 pH at 37 degree C1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.
AID78566In vitro cytotoxicity against human small cell lung cancer H69 cell lines1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.
AID73023In vitro cytotoxicity against GCT cell lines1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.
AID98330In vitro cytotoxicity against L1210 murine lymphocytic leukemia cell lines1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.
AID216274In vitro cytotoxicity against walker rat carcinoma 256 cell lines1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.
AID20912Aqueous solubility was determined1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (33.33)18.7374
1990's9 (60.00)18.2507
2000's1 (6.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.29 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (11.11%)5.53%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]